Famke L. Schneiders
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Famke L. Schneiders has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- Suresh Senan
Department of Radiation Oncology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, 1117 Amsterdam, The Netherlands
10 shared publications Miguel A. Palacios
Amsterdam UMC location Vrije Universiteit Amsterdam, Department of Radiation Oncology, de Boelelaan 1117, Amsterdam, The Netherlands
5 shared publications- Peter S. N. van Rossum
Department of Radiation Oncology, Amsterdam UMC, Amsterdam, the Netherlands; Cancer Treatment & Quality of Life, Cancer Center Amsterdam, Amsterdam, the Netherlands
5 shared publications - Anna M. E. Bruynzeel
Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Radiation Oncology, Amsterdam, The Netherlands
4 shared publications - Berend Jan Slotman
Department of Radiation Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands
4 shared publications - Idris Bahce
Amsterdam UMC, Amsterdam, The Netherlands
4 shared publications
Latest Publications
- Open Access
- 25 May 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 242, 116820
The survival impact of combining radiotherapy and immune checkpoint inhibitors in patients with solid tumors: A systematic review and living meta-analysis of randomized controlled trials
- 25 May 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 242, 116820
Open AccessThe survival impact of combining radiotherapy and immune checkpoint inhibitors in patients with solid tumors: A systematic review and living meta-analysis of randomized controlled trials
- Open Access
- 20 May 2026
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 221, 111599
Efficacy and safety of adrenalectomy and stereotactic ablative radiotherapy (SABR) for adrenal metastases: A systematic review and meta-analysis
- 20 May 2026
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 221, 111599
Open AccessEfficacy and safety of adrenalectomy and stereotactic ablative radiotherapy (SABR) for adrenal metastases: A systematic review and meta-analysis
- Open Access
- 9 May 2026
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 220, 111588
Outcomes of stereotactic ablative radiotherapy or surgery for early-stage lung cancer in patients with interstitial lung disease
- 9 May 2026
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 220, 111588
Open AccessOutcomes of stereotactic ablative radiotherapy or surgery for early-stage lung cancer in patients with interstitial lung disease
- Open Access
- 12 October 2025
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 56, 101056
Re-irradiation of adrenal metastases using MR-guided adaptive SABR: A feasible and effective approach in a high-risk population
- 12 October 2025
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 56, 101056
Open AccessRe-irradiation of adrenal metastases using MR-guided adaptive SABR: A feasible and effective approach in a high-risk population
- Open Access
- 7 July 2025
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 54, 101011
Changes in splenic volumes following stereotactic ablative radiotherapy (SABR) to adrenal tumors
- 7 July 2025
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 54, 101011
Open AccessChanges in splenic volumes following stereotactic ablative radiotherapy (SABR) to adrenal tumors
- Open Access
- 30 September 2024
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 12 (9) , e009799
Single-arm trial of neoadjuvant ipilimumab plus nivolumab with chemoradiotherapy in patients with resectable and borderline resectable lung cancer: the INCREASE study
Background: In non-small cell lung cancer (NSCLC), chemoradiotherapy (CRT) yields pathological complete response (pCR) rates of approximately 30%. We investigated using ipilimumab plus nivolumab (IPI-NIVO) with neoadjuvant CRT in resectable, and borderline resectable NSCLC. Methods: This single-arm, phase-II trial enrolled operable T3-4N0–2 patients with NSCLC without oncogenic drivers. Primary study endpoints were safety, major pathological response (MPR) and pCR. Treatment encompassed platinum-doublet concurrent CRT, IPI 1 mg/kg intravenous and NIVO 360 mg intravenous on day-1, followed by chemotherapy plus NIVO 360 mg 3 weeks later. Thoracic radiotherapy was 50 or 60 Gy, in once-daily doses of 2 Gy. Resections were 6 weeks post-radiotherapy. Results: In a total of 30 patients in the intention-to-treat (ITT) population, grades 3–4 treatment-related adverse events (TRAEs) occurred in 70%, one TRAE grade 5 late-onset pneumonitis on day 96 post-surgery (1/30, 3.3%) occurred, and one non-TRAE COVID-19 death (1/30, 3.3%). pCR and MPR were achieved in 50% (15/30) and 63% (19/30) of the ITT; and in 58% (15/26) and 73% (19/26) of the 26 patients who underwent surgery, respectively. Postoperative melanoma was seen in one non-pCR patient. The R0 rate was 100% (26/26), and no patient failed surgery due to TRAEs. In peripheral blood, proliferative CD8+ T cells were increased, while proliferative regulatory T cells (Tregs) were not. On-treatment, pCR-positives had higher CD8+CD39+ T cells and lower HLA-DR+ Tregs. Conclusions: Neoadjuvant IPI-NIVO-CRT in T3-4N0–2 NSCLC showed acceptable safety with pCR and MPR in 58% and 73% of operated patients, respectively. No patient failed surgery due to TRAEs. Trial registration number: NCT04245514.
- 30 September 2024
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 12 (9) , e009799
Open AccessSingle-arm trial of neoadjuvant ipilimumab plus nivolumab with chemoradiotherapy in patients with resectable and borderline resectable lung cancer: the INCREASE study
Background: In non-small cell lung cancer (NSCLC), chemoradiotherapy (CRT) yields pathological complete response (pCR) rates of approximately 30%. We investigated using ipilimumab plus nivolumab (IPI-NIVO) with neoadjuvant CRT in resectable, and borderline resectable NSCLC. Methods: This single-arm, phase-II trial enrolled operable T3-4N0–2 patients with NSCLC without oncogenic drivers. Primary study endpoints were safety, major pathological response (MPR) and pCR. Treatment encompassed platinum-doublet concurrent CRT, IPI 1 mg/kg intravenous and NIVO 360 mg intravenous on day-1, followed by chemotherapy plus NIVO 360 mg 3 weeks later. Thoracic radiotherapy was 50 or 60 Gy, in once-daily doses of 2 Gy. Resections were 6 weeks post-radiotherapy. Results: In a total of 30 patients in the intention-to-treat (ITT) population, grades 3–4 treatment-related adverse events (TRAEs) occurred in 70%, one TRAE grade 5 late-onset pneumonitis on day 96 post-surgery (1/30, 3.3%) occurred, and one non-TRAE COVID-19 death (1/30, 3.3%). pCR and MPR were achieved in 50% (15/30) and 63% (19/30) of the ITT; and in 58% (15/26) and 73% (19/26) of the 26 patients who underwent surgery, respectively. Postoperative melanoma was seen in one non-pCR patient. The R0 rate was 100% (26/26), and no patient failed surgery due to TRAEs. In peripheral blood, proliferative CD8+ T cells were increased, while proliferative regulatory T cells (Tregs) were not. On-treatment, pCR-positives had higher CD8+CD39+ T cells and lower HLA-DR+ Tregs. Conclusions: Neoadjuvant IPI-NIVO-CRT in T3-4N0–2 NSCLC showed acceptable safety with pCR and MPR in 58% and 73% of operated patients, respectively. No patient failed surgery due to TRAEs. Trial registration number: NCT04245514.
- 12 August 2024
- Published by Elsevier in The Lancet Respiratory Medicine
- Vol. 12 (10) , 748-750
New strategies for patients with limited-stage small-cell lung cancer
- 12 August 2024
- Published by Elsevier in The Lancet Respiratory Medicine
- Vol. 12 (10) , 748-750
New strategies for patients with limited-stage small-cell lung cancer
- Open Access
- 8 June 2024
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 198, 110376
Artificial intelligence-assisted quantitative CT analysis of airway changes following SABR for central lung tumors
- 8 June 2024
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 198, 110376
Open AccessArtificial intelligence-assisted quantitative CT analysis of airway changes following SABR for central lung tumors
- Open Access
- 24 September 2023
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 43, 100680
Clinical outcomes of MR-guided adrenal stereotactic ablative radiotherapy with preferential sparing of organs at risk
- 24 September 2023
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 43, 100680
Open AccessClinical outcomes of MR-guided adrenal stereotactic ablative radiotherapy with preferential sparing of organs at risk